In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer And Rare Diseases Top EU Drug Approvals In 2015

This article was originally published in Scrip

Executive Summary

  • 46 new active substances approved
  • First stem cell therapy
  • First drug for mitochondrial dysfunction
  • 12 new anticancers
  • 16 drugs for rare diseases
  • Five accelerated approvals
  • Four conditional approvals
  • Three exceptional circumstances approvals
  • Second-highest number of CHMP recommendations
  • You may also be interested in...

    

    Long-Awaited EU Review Questions 10-Year Orphan Exclusivity

    The EU Orphan Regulation and the Paediatric Regulation have helped to increase the number of products developed for rare diseases and children, but they both have some shortcomings that need to be addressed, according to an evaluation of the legislation carried out by the EU authorities. The European pharmaceutical industry has warned against opening up the legislation, saying it is “critical to maintain a stable and predictable incentives framework."

    Scottish HTA OKs Neratinib For Early-Stage Breast Cancer

    A product that was initially turned down for marketing approval in the EU has now been given the green light for use on the National Health Service in Scotland, following a similar recommendation in England late last year.

    Coronavirus Notebook: WHO Accelerator Project Languishes, Novel Treatments Are Explored, Gilead Submits US Remdesevir Filing

    Gilead files for US approval of remdesivir and boosts investment in manufacturing capacity, more funding is needed for the global ACT Accelerator initiative, and the US and China are rated among the worst responders to the COVID-19 pandemic. 

    Topics

    UsernamePublicRestriction

    Register

    LL1122113

    Ask The Analyst

    Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

    Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

    All fields are required.

    Please make sure all fields are completed.

    Please make sure you have filled out all fields

    Please make sure you have filled out all fields

    Please enter a valid e-mail address

    Please enter a valid Phone Number

    Ask your question to our analysts

    Cancel